Born to survive: how cancer cells resist CAR T cell therapy
Although chimeric antigen receptor T cells demonstrated remarkable efficacy in patients with
chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This …
chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This …
Treatment strategies for patients with diffuse large B-cell lymphoma
S Poletto, M Novo, L Paruzzo, PMM Frascione… - Cancer treatment …, 2022 - Elsevier
Diffuse large B-cell lymphoma (DLBCL) is nowadays a curable disease with the frontline
treatment R-CHOP, but 30–40% of patients are still unresponsive or relapse thereafter. In …
treatment R-CHOP, but 30–40% of patients are still unresponsive or relapse thereafter. In …
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Despite impressive progress, more than 50% of patients treated with CD19-targeting
chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 …
chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 …
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
Chimeric antigen receptor (CAR) T cells targeting CD19 are a breakthrough treatment for
relapsed, refractory B cell malignancies,,,–. Despite impressive outcomes, relapse with …
relapsed, refractory B cell malignancies,,,–. Despite impressive outcomes, relapse with …
KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma
Background Patients with relapsed or refractory mantle-cell lymphoma who have disease
progression during or after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy …
progression during or after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy …
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
JH Baird, DJ Epstein, JS Tamaresis, Z Ehlinger… - Blood …, 2021 - ashpublications.org
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has significantly improved
outcomes in the treatment of refractory or relapsed large B-cell lymphoma (LBCL). We …
outcomes in the treatment of refractory or relapsed large B-cell lymphoma (LBCL). We …
Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy
JY Spiegel, S Dahiya, MD Jain… - Blood, The Journal …, 2021 - ashpublications.org
COI notes: MDJ: Consultancy, Kite/Gilead, Novartis SD: Advisory Board: Kite/Gilead, Atara
Biotherapeutics LJN: Honorarium: Bayer, Celgene, Genentech, Gilead/Kite, Janssen, Juno …
Biotherapeutics LJN: Honorarium: Bayer, Celgene, Genentech, Gilead/Kite, Janssen, Juno …
Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial
Y Zhang, Y Wang, Y Liu, C Tong, C Wang, Y Guo, D Ti… - Leukemia, 2022 - nature.com
Increasing the remission rate and reducing the recurrence rate can improve the clinical
efficacy of chimeric antigen receptor (CAR) T cell therapy in recurrent/refractory non …
efficacy of chimeric antigen receptor (CAR) T cell therapy in recurrent/refractory non …
CAR-T cells and BiTEs in solid tumors: challenges and perspectives
J Edeline, R Houot, A Marabelle… - Journal of Hematology & …, 2021 - Springer
Chimeric antigen receptor (CAR)-modified T cells and BiTEs are both immunotherapies
which redirect T cell specificity against a tumor-specific antigen through the use of antibody …
which redirect T cell specificity against a tumor-specific antigen through the use of antibody …
Modulation of BCL-2 in both T cells and tumor cells to enhance chimeric antigen receptor T-cell immunotherapy against cancer
Chimeric antigen receptor T-cell (CART) immunotherapy led to unprecedented responses in
patients with refractory/relapsed B-cell non-Hodgkin lymphoma (NHL); nevertheless, two …
patients with refractory/relapsed B-cell non-Hodgkin lymphoma (NHL); nevertheless, two …